• ClipSaver
ClipSaver
Русские видео
  • Смешные видео
  • Приколы
  • Обзоры
  • Новости
  • Тесты
  • Спорт
  • Любовь
  • Музыка
  • Разное
Сейчас в тренде
  • Фейгин лайф
  • Три кота
  • Самвел адамян
  • А4 ютуб
  • скачать бит
  • гитара с нуля
Иностранные видео
  • Funny Babies
  • Funny Sports
  • Funny Animals
  • Funny Pranks
  • Funny Magic
  • Funny Vines
  • Funny Virals
  • Funny K-Pop

Palbociclib combinations on treatment of advanced breast cancer – Video abstract [ID 77033] скачать в хорошем качестве

Palbociclib combinations on treatment of advanced breast cancer – Video abstract [ID 77033] 9 лет назад

скачать видео

скачать mp3

скачать mp4

поделиться

телефон с камерой

телефон с видео

бесплатно

загрузить,

Не удается загрузить Youtube-плеер. Проверьте блокировку Youtube в вашей сети.
Повторяем попытку...
Palbociclib combinations on treatment of advanced breast cancer – Video abstract [ID 77033]
  • Поделиться ВК
  • Поделиться в ОК
  •  
  •  


Скачать видео с ютуб по ссылке или смотреть без блокировок на сайте: Palbociclib combinations on treatment of advanced breast cancer – Video abstract [ID 77033] в качестве 4k

У нас вы можете посмотреть бесплатно Palbociclib combinations on treatment of advanced breast cancer – Video abstract [ID 77033] или скачать в максимальном доступном качестве, видео которое было загружено на ютуб. Для загрузки выберите вариант из формы ниже:

  • Информация по загрузке:

Скачать mp3 с ютуба отдельным файлом. Бесплатный рингтон Palbociclib combinations on treatment of advanced breast cancer – Video abstract [ID 77033] в формате MP3:


Если кнопки скачивания не загрузились НАЖМИТЕ ЗДЕСЬ или обновите страницу
Если возникают проблемы со скачиванием видео, пожалуйста напишите в поддержку по адресу внизу страницы.
Спасибо за использование сервиса ClipSaver.ru



Palbociclib combinations on treatment of advanced breast cancer – Video abstract [ID 77033]

Video abstract of review paper “Impact of palbociclib combinations on treatment of advanced estrogen receptor-positive/human epidermal growth factor 2-negative breast cancer” published in the open access journal OncoTargets and Therapy by Boér. Abstract: Breast cancer is a heterogeneous disease with multiple subgroups based on clinical and molecular characteristics. For the largest subgroup of breast cancers, hormone receptor-positive/human epidermal growth factor 2 (HER2)-negative tumors, hormone treatment is the mainstay of therapy and is likely to result in significant improvement in disease outcomes. However, some of these cancers demonstrate de novo or acquired resistance to endocrine therapy. Despite intensive research to develop new strategies to enhance the efficacy of currently available treatment options for hormone receptor-positive breast cancer, progress has been slow, and there were few advances for a period of 10 years. In 2012, a new molecularly targeted therapeutic strategy, inhibition of mammalian target of rapamycin with everolimus, was introduced into clinical practice. Everolimus, in combination with a steroidal aromatase inhibitor, exemestane, resulted in an increase in progression-free survival, but not overall survival in patients with estrogen receptor (ER)+ve advanced disease who had progressed on hormone therapy. In 2015, the first cyclin-dependent kinases 4/6 (CDK4/6) inhibitor, palbociclib, received accelerated US Food and Drug Administration approval for use in combination with letrozole for the treatment of postmenopausal ER+ve/HER2-ve advanced breast cancer as initial, endocrine-based therapy. The addition of palbociclib to endocrine therapy resulted in longer progression-free survival than letrozole alone. One year later, palbociclib received a new indication, use in combination with fulvestrant, in both premenopausal and postmenopausal females with advanced breast cancer of the same subtype with disease progression following endocrine therapy. Adding palbociclib to fulvestrant resulted in a significantly increased median progression-free survival compared to fulvestrant monotherapy. These new combination regimens of palbociclib with endocrine agents represent an important addition to the therapeutic armamentarium in ER+ve/HER2-ve advanced and metastatic breast cancer. Read the full review paper here: https://www.dovepress.com/impact-of-p...

Comments

Контактный email для правообладателей: [email protected] © 2017 - 2025

Отказ от ответственности - Disclaimer Правообладателям - DMCA Условия использования сайта - TOS



Карта сайта 1 Карта сайта 2 Карта сайта 3 Карта сайта 4 Карта сайта 5